The big opportunities in currencies happen at extremes… That's the moment that you want to consider trading them. I don't trade currencies that often. But when these extremes materialize, I get in. We haven't seen many currency extremes lately. But we are about to… The U.S. dollar has gained roughly 25% in three years against the world's major....More>>>
Popular stock Twitter bounced into resistance this morning on possible acquisition rumors.
Price jumped up 8% into a key resistance target we can plan the next swing trade from this key level.
Let’s do it!
First, check our prior update “Downtrending Twitter Can’t Catch a Break” from January 19th.
From then price did trade lower to retest....More>>>
Stocks discussed on the in-depth session of Jim Cramer’s Mad Money TV Program, Friday, September 9.
The decline in averages on Friday was prompted by the Fed’s stance on the rate hike. “I want you to be prepared ahead of the Fed’s move. That means taking evasive action, because the reward isn’t worth the risk, at least at these elevated prices. I say another,....More>>>
Related AAPL Apple's Near-Term iPhone SE Strength Offsets 6s/6s Plus Weakness Barclays Lowers Apple's Price Target From $121 To $115, Sees Near-Term Pressure Why Tesla Crash Won't Slow The Self-Driving Car Race (Investor’s Business Daily) Related AMCX AMC Networks' 'Fears Realized,'....More>>>
Clovis Oncology, Inc. (NASDAQ: CLVS) is watching its shares hit a new 52-week high after the company reported a key U.S. Food and Drug Administration (FDA) approval. Essentially, the FDA approved Rubraca (rucaparib) tablets as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated, advanced ovarian cancer. These are also patients who have been....More>>>